Close Menu

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis today reported that its full-year 2018 revenues rose 32 percent year over year, driven by instrument adoption in the US and European markets.

Biocartis also announced this morning that it had received CE-IVD marking for the Idylla MSI Test, which was previously available as a research-use only test called Idylla MSI Assay launched last July.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.